Clinical Trial Update: Adding IL-2 to Tebentafusp to Eradicate Cancer Progression [Phase 1, Phase 2]

View source ↗

Summary

Announced clinical trial evaluating adding interleukin-2 to tebentafusp to eradicate cancer progression in uveal melanoma, including metastatic involvement and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uveal Melanoma
• Uveal Melanoma to the Liver

Drugs mentioned

• Interleukin-2 (interleukin-2)
• Tebentafusp (tebentafusp)

Snippet

Sponsor: St Vincent's Hospital, Sydney | Conditions: Uveal Melanoma, Metastatic Uveal Melanoma | Phase 1, Phase 2 | Status: RECRUITING